A phase I/II trial with chimeric monoclonal antibody WX-G250 in combination with low dose interleukin-2 for patients with metastatic renal cell carcinoma
I. Bleumer, J. Beck, Oosterwijk, C. Mala, S. Ullrich, P.F.A. MuldersVolume:
2
Year:
2003
Language:
english
DOI:
10.1016/s1569-9056(03)80389-5
File:
PDF, 199 KB
english, 2003